The Leishmaniasis treatment market mainly includes drugs for visceral leishmaniasis and cutaneous leishmaniasis. Leishmaniasis is a vector-borne disease caused by infection with protozoan parasites belonging to the genus Leishmania. The parasites are transmitted to humans through the bite of female Phlebotomine sand flies. Leishmaniasis is endemic in tropical and subtropical regions across the world. The mainstay treatments for leishmaniasis include pentavalent antimonials, amphotericin B and miltefosine. However, high toxicity and emerging resistance limit their effectiveness. Hence, there is an urgent need for safer and more effective treatment options.

The global Leishmaniasis Treatment Market is estimated to be valued at US$ 79.95 Bn in 2024 and is expected to exhibit a CAGR of 22% over the forecast period from 2024 to 2030.

Key Takeaways

Key players operating in the Global Leishmaniasis Treatment Market Size are Johnson & Johnson, Intrabio, Cyclo Therapeutics, Inc., Kempharm, Inc., Azafaros B.V., StrideBio. Sarepta Therapeutics, Inc. Key players are investing heavily in R&D to develop novel drugs with improved safety profiles. For instance, Johnson & Johnson is evaluating sintilimab injection in phase 3 trials for visceral leishmaniasis.

The demand for leishmaniasis treatment is expected to grow significantly during the forecast period. This can be attributed to rising infection incidence, growing demand for effective therapies, and increasing government focus on leishmaniasis control and elimination programs. According to WHO, an estimated 700,000 to 1 million new cases emerge annually worldwide.

Owing to high infection burden, companies are also focusing on geographic expansion into untapped markets. In 2021, Sarepta Therapeutics announced plans to commercialize its leishmaniasis drug in India and other Asian and African countries. Other players have also strengthened their presence across Latin America, the Middle East and Africa in recent years.

Market drivers

Growing disease prevalence due to factors like population growth, migration, environmental changes, and weakening immunity is a major driver for the leishmaniasis treatment market. According to a study published in PLOS Neglected Tropical Diseases journal in 2022, global prevalence of visceral leishmaniasis increased by around 20% between 1990 and 2016, with over 66,000 annual deaths. The rising infection incidence has necessitated development of more effective therapies.

Geopolitical impacts on leishmaniasis treatment market growth

The current geopolitical instability and conflicts are driving significant population displacements across various regions. This is increasing the risk of Leishmaniasis infections, especially in wartorn countries like Syria, Yemen, and Afghanistan. Refugees and displaced people often live in unhygienic camps or improvised settings with limited access to healthcare. This facilitates the spread of Leishmaniasis throughvector sand flies. The treatment market is witnessing higher demands to curb the rising caseloads in countries experiencing political turmoil and conflicts.

Moreover, cross-border transmissions have also increased owing to population movements. This challenges surveillance and control efforts. Health systems are overwhelmed tending to war-wounded, leaving infectious diseases like Leishmaniasis a lower priority. Geopolitical tensions can also disrupt supply chains and distribution networks of Leishmaniasis drugs. Dependency on imported medicines further complicates matters. Overall, the unstable political environment acrossmany endemic regions is proving detrimental toLeishmaniasis treatment market growth.

Regions contributing majorly to leishmaniasis treatment market value

The Middle East accounts for the largest share of the global Leishmaniasis treatment market in terms of value. This is mainly because countries like Syria, Iran, Iraq, Saudi Arabia lie within disease hyper-endemic regions of theEastern Mediterranean and Middle East.Repeated outbreaks have been reported from this cluster posing a severe public health challenge. The region spanning Central and South Americas including Brazil,Mexico, Colombia, Venezuela also significantly contributes to the total market value due to widespread transmission rates.

Fastest growing region for leishmaniasis treatment market

Africa is anticipated to be the fastest growing region in the leishmaniasis treatment market during the forecast period. This reflects the increasing disease incidence exacerbated by ecological transformations,human activities like construction, irrigation projects, urbanization, and deforestation across sub-Saharan countries. War-torn nations like South Sudan, Somalia, DRC, also face a looming Leishmaniasis crisis in the post-conflict phase caused by population shifts. Developing healthcare infrastructure and growing access to diagnosis and medications will elevate the treatment-seeking rate.

Get More Insights On This Topic: https://www.newsanalyticspro.com/leishmaniasis-treatment-market-analysis-growth-forecast-outlook-2023-2030-2/